Loading...
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
André, F O'Regan, R Ozguroglu, M Toi, M Xu, B Jerusalem, G Masuda, N Wilks, S Arena, F Isaacs, C
André, F
O'Regan, R
Ozguroglu, M
Toi, M
Xu, B
Jerusalem, G
Masuda, N
Wilks, S
Arena, F
Isaacs, C
Citations
Altmetric:
Abstract
Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab.
Description
Date
2014-05
Publisher
Collections
Keywords
Type
Article
Citation
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. 2014, 15 (6):580-91 Lancet Oncol